Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

HOXA9/METTL3/BMI1 axis is required for promoting anthracycline resistance in acute myeloid leukemia cells by modulating BMI1 expression through  mRNA m6A modification

View Full Paper
Ask AI
Bookmark
Share

Authors

HWHao WangDLDai-hong LiuLDLiping Dou

Discussion

Loading...

Member takes

Overview

Observational analysis identified m6A modification's role in drug resistance and apoptosis in acute myeloid leukemia.

Key Points

  • Anthracycline resistance in acute myeloid leukemia cells is driven by the HOXA9/METTL3/BMI1 axis.
  • Overexpression of METTL3 enhances drug resistance, while its inhibition induces apoptosis.
  • Analysis of chromatin accessibility revealed significant differences between resistant and sensitive AML cells.
  • Targeting the METTL3/BMI1 axis may offer a therapeutic strategy for overcoming chemotherapy resistance.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e036https://doi.org/10.1182/blood-2025-5246
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting METTL3 disrupts oncogenic transcriptional programs and activates immune and apoptotic pathways in Acute Myeloid Leukemia2025
  2. 2Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia2025 · 1 citations
  3. 3The role of METTL14 in the progression of chronic myeloid leukemia2025 · 4 citations
  4. 4Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m6A modification2025 · 1 citations
  5. 5Anthracyclines induce epigenetic changes in ALDH1A that promote chemoresistance in AML, revealing a potential treatment strategy co-targeting ALDH1A inhibition with hypomethylating agents2025